Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ('Protagonist' or the 'Company') today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to J&J Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
[email protected]
SOURCE: Protagonist Therapeutics
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Chicago Tribune
an hour ago
- Chicago Tribune
Gary fighting shortage in classroom with online teachers
With less than a month before school begins, Gary Community School Corp. staffers made one thing clear during Thursday's school board meeting – the district is hiring. Staff members and school board members wore white T-shirts with a QR code on the back and the message, 'We are Hiring!' The first day of school is Aug. 7. Teachers are the most prized employees, including special education, physics, and secondary content teachers. Gary's website cited 81 job openings, including 36 teacher vacancies. To ensure students have a qualified teacher in each classroom, the board retained Proximity Learning, an Austin, Texas-based company that operates a virtual teaching program led by licensed teachers. Locally, Lake Ridge Schools have used Proximity teachers and its former superintendent, Sharon Johnson-Shirley, offered a testimonial featured on Proximity's website. She said Lake Ridge had been relying on substitutes, and she praised the impact Proximity teachers provided. In many cases, Gary has been relying on classroom teachers who work under emergency state permits. Those teachers have a bachelor's degree, but they aren't licensed to teach. Chief human resources officer Jovanka Cvitkovich said about one-third of the district's teachers worked under emergency permits last year. She said many had permits that could not be renewed because the teachers didn't meet Indiana's requirements. 'We'd prefer someone who has expertise, albeit on a screen with a classroom facilitator in place,' Cvitkovich said. The district's ultimate goal is to have a live teacher, she said. 'This provides flexibility, they're here for us as that backup…. We can't keep doing the same thing we've been doing for the past seven years, which is having teachers not licensed. This is a backup to make sure students get what they need, which is high-quality instruction.' Chief academic officer Cynthia Treadwell also endorsed Proximity. 'It's a very unique opportunity given what's at stake. We are really trying to drive academic outcomes. When we have teachers that don't have that pedagogy, there's a huge gap. We know high-quality teachers make a difference.' Superintendent Yvonne Stokes said each Proximity teacher would cost the district about $70,000, but the district would also have to hire a facilitator in each classroom as a backup for the online teacher. Proximity vice president Michael Robinson said there's a national teaching shortage with 600,000 open jobs. 'Don't feel like you're in this by yourselves,' he said. Founded in 2009, Robinson said Proximity has served more than 500,000 students in states across the country. The board also gave Superintendent Stokes temporary authority to hire new staff members because the board doesn't have a meeting before school starts. Teachers start work Aug. 4. In other business, the board voted 4-0, without discussion, to allow Gary-based Edgewater Health to offer an on-site student health center at the West Side Leadership Academy. Stokes said the collaboration wouldn't cost the district, other than the space at West Side. Community HealthNet, of Gary, was the other applicant. Board member Danita Johnson-Woods, president and chief executive officer of Edgewater, recused herself from the vote. Cvitkovich said Edgewater has offered day treatment services to the district for the past 50 years, including counseling, crisis and trauma services, teacher training and parenting workshops. She said it should be a seamless transition. Karen Bishop Morris, Edgewater's chief development officer and communications director, said the board's support represented a vote for integrated health services. 'This is an amazing opportunity for us to continue and expand our partnership… improving access to care. We hope it will reduce absenteeism,' she said.
Bloomberg
an hour ago
- Bloomberg
Nvidia's Huang Says China's Military Unlikely to Use US AI Chips
Nvidia Corp. Chief Executive Officer Jensen Huang said the US government doesn't need to be concerned that the Chinese military will use his company's products to improve their capabilities. Addressing the largest concern Washington has cited in placing increasing restrictions on US technology exports to the Asian nation, Huang said the Chinese military will avoid using US technology because of the risks associated with doing so.
Yahoo
an hour ago
- Yahoo
EU pauses trade retaliation against US after Trump's 30% tariff threat
The EU will delay its plan to hit the US with tariffs on €21bn of its annual exports to Europe on Tuesday in the hope of coming to an
